Neurodegenerative dementias;Neurodegenerativní demence

Ceska a Slovenska Neurologie a Neurochirurgie

Volumn 72, Issue 2, 2009, Pages 97-109

  Rektorová, Irena ^a  

^a ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

Alzheimer's disease; Dementia; Dementia with lewy bodies; Frontotemporal dementia; Huntington's disease; Mild cognitive impairment; Parkinson's disease with dementia

Indexed keywords

AMANTADINE; BENZATROPINE; BETA SECRETASE INHIBITOR; BIPERIDEN; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; GAMMA SECRETASE INHIBITOR; HALOPERIDOL; IDAZOXAN; METHYLPHENIDATE; MIRTAZAPINE; OLANZAPINE; PIMOZIDE; PROCYCLIDINE; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SULPIRIDE; TETRABENAZINE; TIAPRIDE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ALZHEIMER DISEASE; ARTICLE; BEHAVIOR THERAPY; COGNITIVE DEFECT; COGNITIVE THERAPY; DEGENERATIVE DISEASE; DEMENTIA; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; FRONTOTEMPORAL DEMENTIA; HUMAN; HUNTINGTON CHOREA; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; OCCUPATIONAL THERAPY; PARKINSON DISEASE; RISK FACTOR; SENILE PLAQUE;

EID: 65249160126     PISSN: 12107859     EISSN: 18024041     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. Growdon JH, Rossor MN (eds). The dementias II. Philadelphia: Elsevier 2007.
2. Rektorová I. Demence. In: Rektor I et al (eds). Centrální poruchy motoriky a demence. Plzeň: Adéla 2003: 10-33.
3. Hort J, Rusina R et al (eds). Pamět' a její poruchy. Pamět' z hlediska neurovědního a klinického. Praha: Maxdorf 2007.
4. Ritchie K, Lovestone S. The dementias. Lancet 2002; 360(9347): 1759-1766.
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Washington: American Psychiatric Association 1994: 143-147.
6. Konrád J. Deprese, pseudodemence, demence. In: Rektorová I (ed). Kognitivní poruchy a demence. Praha: Triton 2007: 21-28.
7. Rektorová I. Diferenciální diagnostika demencí. Psychiatrie 2004; 3: 216-224.
8. Folstein MF, Folstein SE, McHughs PR. "Mini Mental State". A practical method for grading the cognitive state of patients for the clinician. J Psychiatric Res 1975; 12(3): 189-198.
9. Mathuranath PS, Nestor PJ, Berrios GE, Rakowicz W, Hodges JR. A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia. Neurology 2000; 55(11): 1613-1620.
10. Cummings JL, Mega M, Gray K, Rosenberg-Thompson, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44(12): 2308-2314.
11. Waldemar G, Dubois B, Emre M, Georges J, McKeith IG, Rossor M et al. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 2007; 14(1): e1-e26.
12. Ressner P, Hort J, Rektorová I, Bartoš A, Rusina R, Línek V et al. Doporučené postupy pro diagnostiku Alzheimerovy nemoci a dalších onemocnění spojených s demencí. Cesk Slov Neurol N 2008; 71/104(5): 494-501.
13. Koukolík F, Jirák R. Neurobiologie, klinický obraz, terapie. Praha: Galén 2004.
14. Hort J. Markery demence. In: Rektorová I (ed). Kognitivní poruchy a demence. Praha: Triton 2007: 10-20.
15. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV et al. Current concepts in mild cognitive impairment. Arch Neurol 2001; 58(12): 1985-1992.
16. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56(9): 1133-1142.
17. Cummings JL. Alzheimer's disease. N Engl J Med 2004, 351(1): 56-67.
18. Matěj R, Koukolík F. Neuropatologie neurodegenerativních demencí. In: Rektorová I (ed). Kognitivní poruchy a demence. Praha: Triton 2007: 89-108.
19. Imbimbo BP, Lombard J, Pomara N. Pathophysiology of Alzheimer's disease. Neuroimaging Clin N Am 2005; 15(4): 727-753.
20. Scarpini E, Scheltens F, Feldman H. Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol 2003; 2(9): 539-547.
21. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34(7): 939-944.
22. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6(8): 734-746.
23. Consensus report of the Working Group on: Molecular and biochemical markers of Alzheimer's disease. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging 1998; 19(2): 109-116.
24. Hort J, Glosová L, Vyhnálek M, Bojar M, Škoda D, Hladíková M. Tau protein a beta amyloid v likvoru u Alzheimerovy choroby. Cesk Slov Neurol N 2007; 70/103(1): 30-36.
25. Bartoš A. Klinické novinky na poli Alzheimerovy nemoci. In: Rektorová I (ed) Kognitivní poruchy a demence. Praha: Triton 2007: 49-60.
26. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55(3): 306-319.
27. Rosenberg RN. Immunotherapy for Alzheimer disease: the promise and the problem. Arch Neurol 2005; 62(10): 1506-1507.
28. Sheardová K, Hort J, Rusina R, Bartoš A, Línek V, Ressner P et al. Doporučené postupy pro léčbu Alzheimerovy nemoci a dalších onemocnění spojených s demencí. Cesk Slov Neurol N 2007; 70/103: 589-597.
29. Rektorová I, Rektor I. Parkinsonský syndrom. In: Rektor I, Rektorová I et al (eds). Centrální poruchy hybnosti v praxi. Movement disorders. Praha Triton 2003: 21-70.
30. Rektorová I. Demence u Parkinsonovy nemoci a jiných extrapyramidových onemocnění. In: Růžička E et al (eds). Diferenciální diagnostika a léčba demencí. Příručka pro praxi. Praha: Galén 2003: 99-112.
31. Rektorová I. Demence u Parkinsonovy nemoci. Čes Ger Rev 2008; 6: 214-219.
32. Burn DJ, McKeith IG. Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease. Mov Disord 2003; 18 (Suppl 6): S72-S79.
33. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sørensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60(3): 387-392.
34. Cools R, Swainson R, Owen AM et al. Cognitive dysfunction in non-demented Parkinson's disease. In: Wolters ECh, Scheltens PH and Berendse HW (eds). Mental Dysfunction in Parkinson's disease II. Amsterdam: Academic Pharmaceutical Productions 1999: 142-164.
35. Dubois B, Pillon B. Cognitive deficits in Parkinson's disease. J Neurol 1997; 244(1): 2-8.
36. Lees AJ, Smith E. Cognitive deficits in the early stages of Parkinson's disease. Brain 1983; 106(2): 257-270.
37. Galvin JE, Pollack J, Morris JC. Clinical phenotype of Parkinson disease dementia. Neurology 2006; 67(9): 1605-1611.
38. Janvin CC, Larsen JP, Salmon DF, Galasko D, Hugdahl K, Aarsland D. Cognitive profiles of individual patients with Parkinson's disease and dementia: comparison with dementia with lewy bodies and Alzheimer's disease. Mov Disord 2006; 21(3): 337-342.
39. Jellinger KA. What is new in degenerative dementia disorders? Wien Klin Wochenschr 1999; 111(17): 682-704.
40. McKeith IG, Dickson DW, Emre M, O'Brien JT, Feldman H, Cummings J et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65(12): 1863-1872.
41. Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA et al. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord 2007; 22(16): 2314-2324.
42. Rektorova I, Srovnalova H, Kubikova R, Prasek J. Striatal dopamine transporter imaging correlates with depressivew symptoms and Tower of London task performance in Parkinson's disease. Mov Disord 2008; 23(11): 1580-1587.
43. Emre M, Cummings JL, Lane RM. Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences. J Alzheimers Dis 2007; 11(4): 509-519.
44. Rektorová I, Baláž M. Postup u psychotických komplikací Parkinsonovy nemoci. In: Rektor I et al (eds). Parkinsonova nemoc: doporučené postupy diagnostiky a léçby II. Pozdní stadium. Praha: Galén 2004: 23-25.
45. Rektorová I. Farmakoterapie Parkinsonovy nemoci. Farmakoterapie 2007; 6: 611-617.
46. Burton EJ, McKeith IG, Burn DJ, Williams ED, O'Brien JT. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain 2004; 127(4): 791-800.
47. Nagano-Saito A, Washimi Y, Arahata Y, Kachi T, Lerch JF, Evans AC et al. Cerebral atrophy and its relation to cognitive impairment in Parkinson disease. Neurology 2005; 64: 224-229.
48. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24(2): 197-211.
49. Braak H, Rüb U, Jansen Steur EN, Del Tredid K, de Vos RA. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 2005; 64(8): 1404-1410.
50. Aarsland D, Perry R, Brown A, Larsen JP, Ballard C. Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol 2005; 58(5): 773-776.
51. Rektorová I. Kognitivní a behaviorální poruchy u demence při Parkinsonově nemoci a u demence s Lewyho tělísky. Neurol pro praxi 2004; 1: 15-21.
52. Williams DR, de Silva R, Paviour DC, Pittman A, Watt HC, Kilford L et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain 2005; 128(6): 1247-1258.
53. Burn DJ, O'Brien JT. Use of functional imaging in Parkinsonism and dementia. Mov Disord 2003; 18 (Suppl 6): S88-S95.
54. Rektorova I. DaTSCAN for diagnosis. EPNN Journal 2007; 11(1): 14-15.
55. Poewe W. Treatment of dementia with Levvy bodies and Parkinson's disease dementia. Mov Disord 2005; 20 (Suppl 12): S77-S82.
56. Rektorovà I. Psychiatrické symptomy Parkinsonovy nemoci: diagnostika a léčba. Neurol pro praxi 2007; 8: 291-294.
57. Rektorová I. Účinek donelpezilu na demenci u Parkinsonovy nemoi a Alzheimerovy nemoci: Pilotni studie. Cesk Slov Neurol N 2004; 67/100(5): 359-363.
58. McKeith IG, Del Ser T, Spano P, Emre M, Wesnes K, Anand R et al. Efficacy of rivastigmine in dementia with Levvy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000, 356(9247): 2031-2036.
59. Emre M, Aarsland D,AlbaneseA, Byrne EJ, Deuschl G, De Deyn PP et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351(24): 2509-2518.
60. Rektorová I. Rivastigmin v léčbě demence u Parkinsonovy nemoci. Remedia 2006, 6: 609-613.
61. Rektorová I. Frontotemporĺní lobární degenerace - diagnóza z neuro-psychiatrického pomezí. Neurol pro praxi 2006; 4:199-202.
62. Rektorová I. Frontotemporální lobární degenerace. In: Rektorová I (ed) Kognitivní poruchy a demence. Praha: Triton 2007: 61-75.
63. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998, 51(6): 1546-1554.
64. McKhann GM, Albert MIS, Grossman M, Miller B, Dickson D, Trojanowski JQ; Work Group on Frontotemporal Dementia and Pick's Disease. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol 2001; 58(11): 1803-1809.
65. Hodges JR, Davies RR, Xuereb JH, Casey B, Broe M, Bak TH et al. Clinicopathological correlates in frontotemporal dementia. Ann Neurol 2004; 56(3): 399-406.
66. Kertesz A, McMonagle P, Blair M, Davidson W, Munoz DG. The evolution and pathology of frontotemporal dementia. Brain 2005, 128(9): 1996-2005.
67. Godbolt AK, Josephs KA, Revesz T, Warrington EK, Lantos P, King A et al. Sporadic and familial dementia with ubiquitin-positive tau-negative inclusions: clinical features of one histopathological abnormality underlying frontotemporal lobar degeneration. Arch Neurol 2005; 62(7): 1097-1101.
68. Mackenzie IR, Baker M, Pickering-Brown S, Hsiung GY, Lindholm C, Dwosh E et al. The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. Brain 2006, 129(11): 3081-3090.
69. Mott RT, Dickson DW, Trojanowski JQ, Zhukareva V, Lee VM, Forman M et al. Neuropathologic, biochemical, and molecular characterization of the frontotemporal dementias. J Neuropathol Exp Neurol 2005; 64(5): 420-428.
70. Bigio EH. Update on recent molecular and genetic advances in frontotemporal lobar degeneration. J Neuropathol Exp Neurol 2008, 67(7): 635-648.
71. Bigio EH. TAR DNA-binding protein-43 in amyotrophic lateral sclerosis, frontotemporal lobar degeneration, and Alzheimer disease. Acta Neuropathol 2008; 116(2): 135-140.
72. Huey ED, Putnam KT, Grafman J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology 2006; 66(1): 17-22.
73. Victor M, Ropper AH. Huntington chorea. In: Adams RD, Victor M. Principles of Neurology. 7th ed. Columbus, Ohio: The McGraw-Hill Companies 2001: 1121-1125.
74. Vonsattel JP, DiFiglia M. Huntington's disease. J Neuropathol Exp Neurol 1998, 57(5): 369-384.
75. Roth J, Židovská J, Uhrová T, Doubek P, Havrdová E, Koblihová J et al. Huntingtonova nemoc a etické problémy její diagnostiky. Psychiatrie 2001; 4: 251-255.
76. Rektorová I. Chorea. In: Rektor I, Rektorová I et al (eds). Centrální poruchy hybnosti v praxi. Movement disorders. Praha: Triton 2003: 103-107.
77. Claes S, Van Zand K, Legius E, Dom R, Malfroid M et al. Correlations between triplet repeat expansion and clinical features in Huntington's disease. Arch Neurol 1996; 53(8): 714-715.
78. Berardelli A, Noth J, Thompson PD, Bollen EL, Curra A, Deuschl G et al. Pathophysiology of chorea and bradykinesia in Huntington's disease. Mov Dis 1999; 14(3): 398-403.